Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | ACACB | O00763 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | SCN1A | P35498 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14111383 | 0.93 | HRH3 (0.69) | LTA4HACACBALDH1A1MAPK1CYP1A2 | |
| SCHEMBL8245067 | 0.87 | PSMB1 (0.67) | LTA4HACACBALDH1A1HRH3MEN1 | |
| SCHEMBL10085336 | 0.86 | LTA4H (0.61) | LTA4HACACBALDH1A1MAPK1CYP1A2 | |
| SCHEMBL8246113 | 0.85 | LTA4H (0.65) | LTA4HALDH1A1HRH3NPC1RAB9A | |
| SCHEMBL8251179 | 0.85 | PSMB1 (0.69) | LTA4HACACBALDH1A1HRH3 | |
| SCHEMBL4485540 | 0.84 | LTA4H (0.69) | LTA4HALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL8251595 | 0.83 | PSMB1 (0.50) | LTA4HACACBALDH1A1HRH3 | |
| SCHEMBL104326 | 0.82 | MEN1 (0.70) | LTA4HALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL15630158 | 0.82 | MEN1 (0.64) | LTA4HALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL10898384 | 0.81 | ALDH1A1 (0.68) | LTA4HALDH1A1MAPK1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| US-9321774-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090036650-A1 | Compounds and methods for peptide synthesis | BIOGEN IDEC MA INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036650-A1 | Compounds and methods for peptide synthesis | BIOGEN IDEC MA INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | LTA4H 2827/4885ACACB 1072/4885ALDH1A1 1197/4885 |
| US-20090036650-A1 | Compounds and methods for peptide synthesis | PTMS, NPPA, DNPEP | LTA4H 2593/4885ACACB 3519/4885ALDH1A1 4847/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | LTA4H 2077/4885ACACB 2447/4885ALDH1A1 4077/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | LTA4H 2064/4885ACACB 2404/4885ALDH1A1 4110/4885 |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | CHRM1, CHRM2, CHRM3 | LTA4H 3616/4885ACACB 4716/4885ALDH1A1 3148/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | LTA4H 2077/4885ACACB 2447/4885ALDH1A1 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.